Introduction {#sec1}
============

Proximal symphalangism (SYM1) is a hereditary disorder manifested by ankylosis of the proximal interphalangeal joints, carpal and tarsal bone fusion, and conductive hearing loss in some cases \[[@B1]\]. The typical features of SYM1 are reduced proximal interphalangeal joint space, symphalangism of the 4th and/or 5th finger \[[@B2],[@B3]\]. The estimated prevalence of SYM1 is less than 1/1000000 with autosomal dominant inherited pattern \[[@B4],[@B5]\]. And the first family with ankylosis of the proximal interphalangeal joints was reported and named as symphalangism in 1916 \[[@B6]\].

At present, at least two types of SYM1 have been identified in the clinic. One is proximal symphalangism-1A (SYM1A; OMIM [185800](https://omim.org/entry/185800)), which was caused by genetic variants in *NOG* (*noggin*), another is proximal symphalangism-1B (SYM1B; OMIM [615298](https://omim.org/entry/615298)), which resulted from *GDF5* (*growth differentiation factor 5*) mutations \[[@B2],[@B7]\]. However, due to the extensive pleiotropy, several other diseases may be also related to *NOG*, such as tarsal-carpal coalition syndrome, multiple synostoses syndrome, and brachydactyly, etc. \[[@B8]\]. Hence, detection the genetic lesion of the patients with SYM1 may further confirm the clinical diagnosis and help us to understand the development of bone.

In the present study, we enrolled a family with SYM1 from central south region of China. The aim of the present study was to detect the genetic lesion of the affected individuals by employing whole exome sequencing and bioinformatics analysis.

Materials and methods {#sec2}
=====================

Subjects and ethical approval {#sec2-1}
-----------------------------

The proband ([Figure 1](#F1){ref-type="fig"}A, III:2) was a 6-year-old boy from a non-consanguineous Chinese family. According to the family history investigation, mother (II:4) and grandfather (I:1) of proband also had the phenotype of limited fingers bilaterally, they may be patients with SYM1. We found the fourth to fifth fingers bilaterally of his mother were limited after preliminary diagnosis. Unfortunately, the proband's mother refused further diagnosis and treatment and grandfather has already passed away. The photographs showed the second to fifth fingers and toes bilaterally of the proband were limited and cannot make a fist ([Figure 1](#F1){ref-type="fig"}B). The radiographs indicated the reduced proximal interphalangeal joint space and further confirmed the clinical diagnosis ([Figure 1](#F1){ref-type="fig"}C). No other significant phenotypes were found, such as hearing loss.

![The clinical data of the family with SYM1\
(**A**) The pedigree of this family. Black circles/squares are affected, white circles/squares are unaffected. Arrow indicates the proband. The question mark indicates that the illness is uncertain. (**B**) The proband showed the symphalangism of second to fifth fingers. (**C**) Hands X-ray of III-2. The red circles and arrows marked the abnormal regions.](bsr-40-bsr20200509-g1){#F1}

The Review Board of the Xiangya Hospital of the Central South University approved the present study. Given the proband is too young, written consent forms were signed by his parents as guardians.

Genetic analysis {#sec2-2}
----------------

Genomic DNA was prepared from peripheral blood of the patients and other all participants using a DNeasy Blood &Tissue Kit (Qiagen, Valencia, CA, U.S.A.). Genomic DNA was extracted from the peripheral blood lymphocytes of all family members by using a DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA, U.S.A.) following the manufacturer's instruction. The central part of the whole exome sequencing was provided by the Novogene Bioinformatics Institute (Beijing, China). The exomes were captured using Agilent SureSelect Human All Exon V6 kits, and high-throughput sequencing was performed using Illumina HiSeq X-10. The necessary bioinformatics analyses, including reads, mapping, variant detection, filtering, and annotation, were also endowed by Novogene Bioinformatics Institute \[[@B9]\].

The strategies of data filtering refer to our previous study \[[@B9]\]: (a) variants within intergenic, intronic, and UTR regions as well as synonymous mutations were excluded for later analysis; (b) variants with MAF\>0.01 in the 1000 Genomes project, dbSNP132 were excluded; (c) variants with MAF\>0.01 in genome aggregation database (gnomAD) (<http://gnomad.broadinstitute.org/>) were further precluded; (d) SIFT, Polyphen-2 and MutationTaster were utilized to predict the possible impacts of variants. (e) Co-segregation analysis was conducted in the family.

Result {#sec3}
======

The WES raw data had a mean depth of 125.66 on target, target region coverage of 98.05%, target region coverage (at least 10×) of 97.27%, indicating the high sequencing quality. After data filtering, only 16 variants were included in [Table 1](#T1){ref-type="table"}. We then further performed bioinformatic analysis including Inheritance pattern and OMIM clinical phenotypes analysis (<https://www.omim.org/>), ToppGene gene function analysis (<https://toppgene.cchmc.org/>) and The American College of Medical Genetics and Genomics (ACMG) classification, we highly suspected the unknown variant (NM_005450, c.635_636insG, p.Q213Pfs\*57) of *NOG*, belonging to PM1, PM2, PM4, PP1, PP3, and PP4 (likely pathogenic) in ACMG guidelines \[[@B10]\], was the genetic lesion of the family ([Figure 2](#F2){ref-type="fig"}A). The result of co-segregation analysis showed the same unknown variant exist in mother of proband but not in his father. The unknown variant, which led to alteration of amino acid residues after position 212 and a prolonged protein ([Figure 2](#F2){ref-type="fig"}B), was predicted as "Disease Causing" (0.99) by MutationTaster (<http://www.mutationtaster.org/>) and not found on the 1000 Genome Browser, the gnomAD Browser and the Exome Variant Server, and was not presented in 200 control cohorts. Multiple alignment of noggin orthologs in other animal species showed that amino acid sequence after position 212 was highly conserved ([Figure 2](#F2){ref-type="fig"}C).

![The genetic analysis of the variant\
(**A**) Sanger DNA sequencing chromatogram demonstrates the heterozygosity for a *NOG* variant (c.635_636insG, p.Q213Pfs\*57). (**B**) Rope diagram of noggin--BMP7 complex (SMTL ID: 1m4u.1), the upper and lower parts are noggin dimer and BMP7 dimer, respectively. The arrows and words indicate the Q213 site, the red amino acids rope after Q213 was affected in the patient. (**C**) Alignment of the amino acid sequences of noggin. The affected amino acids locate in the highly conserved amino acid region in different species (from Ensembl). The arrow and words show the Q213 site.](bsr-40-bsr20200509-g2){#F2}

###### The gene list after data filtering in the family with SYM1

  Chr   Pos         RB   AB   Gene     Mutation                                  OMIM                                          Allele frequency   Topp gene                                             ACMG                           
  ----- ----------- ---- ---- -------- ----------------------------------------- --------------------------------------------- ------------------ ----------------------------------------------------- ------------------------------ ------------------------
  1     220275877   C    T    IARS2    NM_018060; c.C790T: p.H264Y               AR: growth hormone deficiency                 Unknown variant    Isoleucyl-tRNA aminoacylation                         PM2, BP6                       Uncertain significance
  2     196681652   A    G    DNAH7    NM_018897; c.T9461C:p.V3154A              \-                                            Unknown variant    Inner dynein arm assembly                             PM2, PP1, PP3                  Uncertain significance
  2     233388655   G    A    PRSS56   NM_001195129; c.G1186A: p.E396K           AR: microphthalmia                            Unknown variant    Serine-type endopeptidase activity                    PM2, BP6                       Uncertain significance
  5     118485627   C    T    DMXL1    NM_001290321; c.C4105T:p.R1369C           --                                            Unknown variant    Vacuolar acidification                                PM2, PP1, PP3                  Uncertain significance
  8     99116733    A    G    HRSP12   NM_005836; c.T335C: p.V112A               --                                            Unknown variant    --                                                    PM2, PP1, PP3                  Uncertain significance
  9     119461126   G    A    TRIM32   NM_001099679; c.G1105A: p.G369R           AR: Bardet--Biedl syndrome                    Unknown variant    Tat protein binding                                   PM2, BP6                       Uncertain significance
  12    992601      T    G    WNK1     NM_014823; c.T2789G: p.F930C              AR: neuropathy; AD: pseudohypoaldosteronism   Unknown variant                                                          PM1, PM2                       Uncertain significance
  12    49522372    A    C    TUBA1B   NM_006082; c.T725G: p.L242R               \-                                            Unknown variant    Chloride channel inhibitor activity                   PM2, PP1, PP3                  Uncertain significance
  17    54672219    G    GG   NOG      NM_005450: c.635_636insG: p. Q213PfsX57   AD: symphalangism                             Unknown variant    Fibroblast growth factor receptor signaling pathway   PM1, PM2, PM4, PP1, PP3, PP4   Likely pathogenic
  17    71420107    G    A    SDK2     NM_001144952; c.C1708T: p.R570W           --                                            Unknown variant    Camera-type eye photoreceptor cell differentiation    PM2, PP1, PP3                  Uncertain significance
  18    13071096    G    A    CEP192   NM_032142; c.G5233A: p.E1745K             --                                            Unknown variant    Phosphatase binding                                   PM2, PP1, PP3                  Uncertain significance
  19    39321974    T    G    ECH1     NM_001398; c.A235C: p.N79H                --                                            Unknown variant    Δ3,5-Δ2,4-Dienoyl-CoA isomerase activity              PM2, PP1, PP3                  Uncertain significance
  19    56128115    T    C    ZNF865   NM_001195605; c.T3131C: p.L1044P          --                                            Unknown variant    --                                                    PM2, PP1, PP3                  Uncertain significance
  20    25457050    C    CA   NINL     NM_025176; c.2876_2877insT: p.E959Dfs15   --                                            Unknown variant    Calcium ion binding                                   PM2, PP1, PP3                  Uncertain significance
  20    30785333    G    A    PLAGL2   NM_002657; c.C413T: p.T138M               --                                            Unknown variant    Chylomicron assembly                                  PM2, PP1, PP3                  Uncertain significance
  X     131188838   G    T    STK26    NM_001042452; c.G222T:p.L74F              --                                            Unknown variant    Microvillus assembly                                  PM2, PP1, PP3                  Uncertain significance

CHR, chromosome; POS, position; RB, reference sequence base; AB, alternative base identified; AR, autosomal recessive; AD, autosomal dominant; BP, benign supporting; PP, pathogenicity supporting; PM, pathogenicity moderate; PVS, pathogenicity very strong. The data of allele frequency were obtained from 1000G, ESP, and ExAC databases.

Discussion {#sec4}
==========

In the present study, we enrolled a family with SYM1 from China. By employing whole exome sequencing, we identified an unknown frameshift variant (c.635_636insG, p.Q213Pfs\*57) in the affected members. The variant resulted in the extension of noggin protein which may affect the function of the protein. Bioinformatics analysis further predicted this variant as disease-causing variant. Our study is consistent with previous studies which indicated that variants in *NOG* gene may lead to SYM1 and other bone diseases \[[@B11]\].

The human *NOG* gene encoding noggin protein is located on chromosome 17q22, and it consists of one exon, spanning approximately 1.9 kilobases (kb). Noggin, the first identified BMP antagonist, is posttranslationally modified and secreted as a disulfide-bonded homodimer. BMPs play essential roles in skeletogenesis including recruiting mesenchymal cells, promoting mesenchymal cell proliferation and differentiation into chondroblasts and osteoblasts, and inducing apoptosis to form joints \[[@B12]\]. Noggin can bind to BMPs and inhibit the interactions of BMPs and BMP-specific recptors, and therefore negatively regulates BMP-induces osteogenesis \[[@B15],[@B16]\]. In the present study, the unknown variant was not located at the interface between the two molecules in noggin--BMP7 complex (SWISS-MODEL Template Library, ID: [1m4u.1](https://swissmodel.expasy.org/repository/uniprot/1m4u.1)), and no templates of sufficient quality to build a homology model were found for the changed sequence ([Figure 2](#F2){ref-type="fig"}B). Whereas, according to the complex model and the prolonged sequence, we suspected the variant presumably affected the binding of noggin homodimer and further disrupt the structure of noggin--BMP7 complex, which actived the BMP signal pathway and lead to bone diseases. Further research is needed to confirm this hypothesis.

On the basis of reported papers, multiple bone diseases are associated with *NOG* mutations \[[@B17]\]. For example, at present, over 50 mutations of *NOG* involved in wide variety of bone development anomalies, including tarsal/carpal coalition syndrome, brachydactyly, multiple synostoses syndrome, stapes ankylosis with broad thumbs and toes, have been reported \[[@B5],[@B18]\]. Even the same variants of *NOG* can lead to different phenotypes between different families or different affected members of the same family, see [Table 2](#T2){ref-type="table"} \[[@B19],[@B20]\]. Meanwhile, the variant was the sixth unknown variant reported in Chinese population, which indicated there were still a lot of unknown variants to be discovered in Chinese population. Here, we summarized the reported *NOG* mutations in [Table 2](#T2){ref-type="table"}, which may make us to understand the function of noggin better.

###### The summary of reported mutations in NOG

  --------------------------------------------------------------------------------------------------------------------------
  No.   Mutation                               Phenotypes                                                    PMID
  ----- --------------------- ---------------- ---------------------------------- -------------- ----------- ---------------
  1     c\. 58delC            p\. Leu20fs      SYNS1                              Hearing loss   --          11846737

  2     c\. 103C\>G           p\. Pro35Ala     BDB                                --             --          17668388

  3     c\. 103C\>T           p\. Pro35Ser     TCC                                Hearing loss   Hyperopia   18440889

  4     c\. 103C\>T           p\. Pro35Ser     SYM1                               Hearing loss   --          11857750

  5     c\. 103C\>T           p\. Pro35Ser     BDB                                --             --          17668388

  6     c\. 104C\>G           p\. Pro35Arg     SYM1                               --             --          10080184

  7     c\. 104C\>G           p\. Pro35Arg     TCC                                --             --          11545688

  8     c\. 106G\>C           p\. Ala36Pro     BDB                                --             --          17668388

  9     c\. 110C\>G           p\. Pro37Arg     TCC                                Hearing loss   --          15264296

  10    c\. 124C\>G;\         p\. Pro42Ala;\   TCC                                Hearing loss   --          15736221
        c. 149C\>G            p. Pro50Arg                                                                    

  11    c\. 124C\>T           p\. Pro42Ser     SYM1                               --             --          31370824

  12    c\. 125C\>G           p\. Pro42Arg     SYNS1                              --             --          18204269

  13    c\. 124C\>A           p\. Pro42Thr     SYNS1                              --             --          23732071

  14    c\. 125C\>T           p\. Pro42Leu     SYNS1                              Hearing loss   --          25241334

  15    c.130_131insGG        p\. Val44fs      TCS                                Hearing loss   Hyperopia   15699718

  16    c\. 137T\>C           p\. Leu46Pro     SYM1                               --             --          22855651

  17    c\. 142G\>A           p\. Glu48Lys     BDB                                --             --          17668388

  18    c\. 142G\>A           p\. Glu48Lys     POF and SYM1                       Hearing loss   --          15066478

  19    c\. 163G\>T           p\. Asp55Tyr     SYM1                               --             --          31105738

  20    c\. 252_253insG       p\. Glu85fs      SABTT                              Hearing loss   Hyperopia   12089654

  21    c\. 261_262insG       p\. Pro88fs      SYNS1                              Hearing loss   Hyperopia   25241334

  22    c\. 271G\>T           p\. Gly91Cys     FOP                                --             --          11503156

  23    c\. 274G\>C           p\. Gly92Arg     FOP                                --             --          11503156

  24    c\. 275G\>A           p\. Gly92Glu     FOP                                --             --          11503156

  25    c\. 283G\>A           p\. Ala95Thr     FOP                                --             --          16080294

  26    c\. 304delG           p\. Ala102fs     SYM1                               Hearing loss   Hyperopia   21358557

  27    c\. 328C\>T           p\. Gln110X      SABTT                              Hearing loss   Hyperopia   12089654

  28    c\. 386T\>A           p\. Leu129X      SYM1                               Hearing loss   --          11846737

  29    c\. 391C\>T           p.Gln131X        SABTT                              Hearing loss   Hyperopia   21358557

  30    c\. 397A\>T           p\. Lys133X      SABTT                              Hearing loss   Hyperopia   27508084

  31    c\. 406C\>T           p\. Arg136Cys    SYM1                               Hearing loss   --          24735539

  32    c\. 450G\>C           p\. Trp150Cys    SYM1                               Hearing loss   --          25888563

  33    c\. 452C\>A           p\. Ser151X      SYNS1                              Hearing loss   --          25241334

  34    c\. 463T\>A           p\. Cys155Ser    SYM1                               Hearing loss   --          22288654

  35    c\. 499C\>G           p\. Arg167Gly    BDB                                --             --          17668388

  36    c\. 499C\>T           p\. Arg167Cys    SYM1                               --             --          24326127

  37    c\. 551G\>A           p\. Cys184Tyr    SYM1                               --             --          11846737

  38    c\. 551G\>T           p\. Cys184Phe    SYM1                               Hearing loss   Hyperopia   22288654

  39    c\. 559C\>T           p\. Pro187Ser    BDB                                --             --          17668388

  40    c\. 559C\>G           p\. Pro187Ala    SYM1                               Hearing loss   --          25391606

  41    c\. 561delC           p\. Pro187fs     TCS                                Hearing loss   Hyperopia   15699718

  42    c\. 565G\>T           p\. Gly189Cys    SYM1                               --             --          10080184

  43    c\. 568A\>G           p\. Met190Val    SYNS1                              Hearing loss   --          18204269

  44    c\. 608T\>C           p\. Leu203Pro    TCS                                Hearing loss   Hyperopia   15699718

  45    c\. 611G\>T           p\. Arg204Leu    TCC                                --             --          11545688

  46    c\. 611G\>G           p\. Arg204Gln    TCC                                --             --          29159868

  47    c\. 614G\>A           p\. Trp205X      SYNS1                              --             --          16532400

  48    c\. 615G\>C           p\. Trp205Cys    Facioaudiosymphalangism syndrome   Hearing loss   Hyperopia   15770128

  49    c\. 615G\>C           p\. Trp205Cys    SABTT                              Hearing loss   Hyperopia   19471170

  50    c\. c.635_636insG     p.Q213PfsX57     SYM1                               --             --          Present study

  51    c\. 645C\>A           p\. Cys215X      SABTT                              Hearing loss   Hyperopia   22288654

  52    c\. 649T\>G           p\. Trp217Gly    SYNS1                              --             --          10080184

  53    c\. 659T\>A           p\. Ile220Asn    SYM1                               --             --          10080184

  54    c\. 659_660delinsAT   p\. Ile220Asn    SYM1                               --             --          10080184

  55    c\. 664T\>G           p\. Tyr222Asp    SYM1                               --             --          10080184

  56    c\. 665A\>G           p\. Tyr222Cys    SYM1                               --             --          10080184

  57    c\. 665A\>G           p\. Tyr222Cys    TCC                                --             --          11545688

  58    c\. 668C\>T           p\. Pro223Leu    SYM1                               --             --          10080184

  59    c\. 682T\>G           p\. Cys228Gly    SABTT                              Hearing loss   Hyperopia   26211601

  60    c\. 682T\>A           p\. Cys228Ala    SYNS1                              Hearing loss   Hyperopia   25391606

  61    c\. 689G\>A           p\. Cys230Tyr    SYNS1                              --             Hyperopia   26994744

  62    c\. 690C\>G           p\. Cys230Trp    SYM1                               Hearing loss   --          31694554

  63    c\. 696C\>G           p\. Cys232Trp    SYNS1                              Hearing loss   Hyperopia   20503332
  --------------------------------------------------------------------------------------------------------------------------

SYNS1, multiple synostosis syndrome; BDB, brachydactyly type B; TCC, Trasal--Carpal coalition syndrome; SYM1, proximal symphalangism; TCS, Teunissen--Cremers syndrome; POF, premature ovarian failure; SABTT, stapes ankylosis with broad thumbs and toes; FOP, fibrodysplasia ossificans progressiva.

In additional to major bone diseases, patients with *NOG* mutations are often accompanied by other phenotypes, such as conductive hearing loss and hyperopia. In [Table 2](#T2){ref-type="table"}, we can find that these phenotypes are not always present in the same mutations or in different mutations at the same sites. Besides, in some papers, hearing loss do not exist in all affected members of same families \[[@B5],[@B18]\]. These results seem to indicate that conductive hearing loss and hyperopia may appear randomly in patients with *NOG* mutations; whereas, in contrast with most NOG mutations that have been reported in kindreds with SYM1 and SYNS1, the mutations observed in families with stapes ankylosis without SYM1 are predicted to disrupt the cysteine-rich C-terminal domain \[[@B21],[@B22]\]. In short, the relationship between *NOG* and these phenotypes is still unclear, further research is needed to understand that. Some patients with *NOG* mutations can also have nasal bone, elbow, shoulder, and spine anomalies except for hands and feet \[[@B11],[@B14]\], suggested noggin protein plays an essential and extensive role in bone development.

In summary, we investigated a Chinese family with SYM1 and an unknown frameshift variant (c.635_636insG, p.Q213Pfs\*57) was detected by whole exome sequencing. According to ACMG standards and guidelines, this variant was categorized as likely pathogenic (PM1, PM2, PM4, PP1, PP3 and PP4) and identified as the genetic lesion of the family. Our study expanded the spectrum of *NOG* mutations and contributed to genetic counseling and diagnosis of patients with SYM1.
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